Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Update on Tozadenant Trial for Parkinson’s

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.


On 11/15/17, Acorda Therapeutics, Inc. announced that several people living with Parkinson's who participated in the Phase III trial for tozadenant experienced agranulocytosis — a severe drop in the number of white blood cells which fight infection — leading to cases of sepsis and five fatalities. Participants in the trial will now have blood cell count monitoring increased from monthly to weekly.  The study has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

Tozadenant is an oral adenosine A2a receptor antagonist currently in Phase III development as an adjunctive treatment to levodopa in Parkinson’s disease patients to reduce OFF time.

Statement from the Parkinson’s Foundation

Our thoughts are with the family members who lost a loved one enrolled in this trial. Their participation in clinical research will ultimately help make life better for the people diagnosed with Parkinson's in the future. 

The Parkinson’s Foundation remains confident that Acorda and the FDA will investigate this rare event. Clinical trials in Parkinson’s disease — from oral therapies to surgical treatments — have had a strong safety record and they are critical in testing the safety and efficacy of investigational therapies.

In order to discover new PD therapies, we rely on brave and altruistic people, like the ones in this trial, to participate in clinical research. The Parkinson’s Foundation remains committed to supporting clinical research through our global network of Centers of Excellence and Parkinson’s Advocates in Research.

If you would like more information about the benefits and risks of clinical trial participation, learn more here.  If you have questions or concerns, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).

Thursday, November 16, 2017
Parkinson’s Foundation Announces New Podcast With Research, Findings And Advice For Patients, Healthcare Professionals, And General Community
Tuesday, August 1, 2017

'Substantial Matters: Life and Science of Parkinson's' Podcast Now Available Online

Parkinson’s Foundation Appoints Sean Kramer as Chief Development Officer
Tuesday, July 11, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced its hiring of Sean Kramer as Senior Vice President, Chief Development Officer. The noted non-profit leader will oversee fundraising initiatives for the national organization, working from its offices in New York and Miami.

The Parkinson’s Foundation’s Fall Moving Day® Walks Fund Local Parkinson’s Programs
Thursday, June 8, 2017

Seven Cities Receive Community Grants 

Parkinson’s Foundation Mourns the Loss of Tom Isaacs
Thursday, June 8, 2017

The Parkinson’s Foundation mourns the loss of Tom Isaacs, a dear friend and renowned global advocate for the Parkinson’s community. Tom passed away on May 31 at the age of 49.

Tom was diagnosed with young onset Parkinson’s more than 20 years ago. He quickly became active in the fight against Parkinson’s in his native UK and as part of the global community.

Parkinson’s Foundation to Host “World Without Parkinson’s” Symposium on Thursday, June 1 to Mark 60th Anniversary
Wednesday, May 31, 2017

Scientific Progress in Next 20 Years Due to Outpace the Last 200

Parkinson’s Foundation Welcomes New Patient Advisors
Wednesday, May 24, 2017

Five New Members Added to Advisory Council to Improve Lives of People Living With Parkinson’s

New York, NY, and Miami, FL — The Parkinson’s Foundation is pleased to welcome five new members to its People with Parkinson’s Advisory Council.  The appointments reflect the foundation’s ongoing commitment to engage with the community in its work to create a world without Parkinson’s disease.

Fifth Annual Celebrate Spring Boston Raises More Than $30,000 for Parkinson’s Foundation
Thursday, May 11, 2017

Boston Area Residents Inspire Fellow Young Professionals to End Parkinson’s

Parkinson’s Foundation Welcomes Paul H. Nathan to Board of Directors
Wednesday, May 3, 2017

New York, NY and Miami, FL — The Parkinson’s Foundation is pleased to announce the election of financial services executive Paul H. Nathan of San Francisco, CA, to its Board of Directors. The appointment was announced following a meeting of the board on April 27.

Parkinson’s Foundation to Host “World Without Parkinson’s” Scientific Symposium on June 1 in NYC
Friday, April 21, 2017

The Parkinson’s Foundation invites health innovators to join World Without Parkinson’s on Thursday, June 1 in New York, NY. The cutting-edge scientific event marks the 200th anniversary of James Parkinson’s, “An Essay on the Shaking Palsy.”

FDA Allows Marketing of a Genetic Test for Medical Conditions Including Parkinson’s
Thursday, April 6, 2017

Earlier today, the US Food and Drug Administration (FDA) announced that it will allow direct marketing to consumers of a genetic test that identifies predispositions for 10 medical conditions, including Parkinson’s. Such tests are referred to as direct-to-consumer or DTC.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.